Pomalidomide
Pomalidomide is an active ingredient of the class «immunosuppressive drug».
Chemical compound
Boxed warning (US label)
EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM EMBRYO-FETAL TOXICITY • POMALYST is contraindicated in pregnancy.
What it is used for
- Myelofibrosis
- Plasma cell leukemia
- Amyloidosis
- Immune disorder
- Multiple myeloma
POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression…
Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
How it works
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
Class: immunosuppressive drug
Common side effects
The following clinically significant adverse reactions are described in detail in other labeling sections: • Embryo-Fetal Toxicity • Venous and Arterial Thromboembolism • Increased Mortality in Patients with Multiple Myeloma When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone • Hematologic…
Who should not take it
Pregnancy • Hypersensitivity 4.1 Pregnancy POMALYST is contraindicated in females who are pregnant. POMALYST can cause fetal harm when administered to a pregnant female.
Pregnancy and breastfeeding
Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in females exposed to POMALYST during pregnancy as well as female partners of male patients who are exposed to POMALYST. This registry is also used to understand the…
Interactions
Brand names
United States
Pomalyst
European Union
Imnovid (previously Pomalidomide Celgene) · Pomalidomide Accord · Pomalidomide Krka · Pomalidomide Teva · Pomalidomide Viatris · Pomalidomide Zentiva
Canada
Apo-Pomalidomide · Jamp Pomalidomide · Nat-Pomalidomide · Pomalyst · Reddy-Pomalidomide · Sandoz Pomalidomide
Other trade names
Imnovid
Approval status
- US Food and Drug Administration
- prescription · since 2013
- European Medicines Agency
- authorised · since 2013
- Health Canada
- prescription · marketed
- First approval anywhere
- 2013
Codes
- ATC
- L04AX06
- RxNorm CUI
- 1369713
- ChEMBL
- CHEMBL43452
- PubChem CID
- 134780
- UNII
- D2UX06XLB5
- Wikidata
- Q7227206
Frequently asked questions
What is Pomalidomide used for?
Pomalidomide is used for: Myelofibrosis, Plasma cell leukemia, Amyloidosis, Immune disorder, and Multiple myeloma.
What kind of medicine is Pomalidomide?
Pomalidomide is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Pomalidomide?
Brand names of Pomalidomide include Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Accord, Pomalidomide Krka, Pomalidomide Teva, Pomalidomide Viatris, Pomalidomide Zentiva, and Apo-Pomalidomide.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)